Suppressive Therapy for Recurrent Genital Herpes

Primary Indication and Benefits

The Centers for Disease Control and Prevention (CDC) recommends daily suppressive therapy as the cornerstone management strategy for patients experiencing frequent genital herpes recurrences, reducing disease burden in affected individuals 1, 2
Daily suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent outbreaks (defined as ≥6 recurrences per year) 1, 3, 4
Reduces asymptomatic viral shedding, though it does not eliminate it completely, potentially decreasing transmission risk to sexual partners 1, 3, 5
Improves quality of life by preventing the physical discomfort, psychological distress, and social impact of recurrent outbreaks 1
Provides convenient once-daily dosing (500 mg to 1 g daily), which improves adherence compared to more frequent acyclovir regimens 1, 5

The CDC guidelines establish that long-term valacyclovir therapy has documented safety for 1 year of continuous use in immunocompetent patients with genital herpes 1, 5
No clinically significant acyclovir resistance has emerged in immunocompetent patients receiving suppressive therapy 1, 5
For patients with <10 recurrences per year, valacyclovir 500 mg once daily is effective 1, 5
For patients with ≥10 recurrences per year, valacyclovir 1,000 mg once daily or 250 mg twice daily provides better suppression 1, 5

Patients with ≥6 recurrences per year are the primary candidates for daily suppressive therapy 1, 4
After 1 year of continuous suppressive therapy, discontinuation should be discussed to assess the patient's psychological adjustment to genital herpes and current recurrence rate 1, 3, 4, 5
Suppressive therapy does not eradicate the virus or completely prevent transmission—patients must be counseled that asymptomatic viral shedding can still occur 1, 3, 4

Immunocompromised patients may require higher doses: valacyclovir 500 mg twice daily (rather than once daily) is recommended for suppressive therapy in HIV-infected individuals 3
Prolonged or severe episodes of genital or perianal herpes are more common in HIV-infected patients 1, 5

The Centers for Disease Control and Prevention recommends acyclovir 400 mg twice daily as an alternative option with documented safety for up to 6 years of continuous use 6
The Centers for Disease Control and Prevention suggests valacyclovir 500 mg twice daily for suppressive therapy in HIV-infected individuals 6, 7
The Centers for Disease Control and Prevention recommends famciclovir 250 mg twice daily as another effective alternative for chronic suppressive therapy 6

The Centers for Disease Control and Prevention states that suppressive therapy has documented safety for up to 6 years with acyclovir 6

The Centers for Disease Control and Prevention notes that acyclovir, valacyclovir, and famciclovir are occasionally associated with nausea or headache, but these are generally mild 7
The Centers for Disease Control and Prevention advises that no laboratory monitoring is needed in patients receiving suppressive therapy unless they have substantial renal impairment 7

The Centers for Disease Control and Prevention warns that thrombotic thrombocytopenic purpura/hemolytic uremic syndrome has been reported in HIV-infected patients treated with high-dose valacyclovir, but has NOT been reported at doses used for suppressive therapy of HSV infection 6, 7

The Centers for Disease Control and Prevention recommends that treatment failure related to resistance should be suspected if lesions do not begin to resolve within 7-10 days after initiation of therapy 6, 7
The Centers for Disease Control and Prevention suggests that for suspected acyclovir-resistant HSV, viral culture should be obtained and susceptibility testing performed if virus is isolated 6
The Centers for Disease Control and Prevention states that IV foscarnet is the treatment of choice for acyclovir-resistant HSV 6, 7

The Centers for Disease Control and Prevention advises against prescribing valacyclovir 500 mg once daily for HIV-infected patients; they require 500 mg twice daily 6